Description
Recombinant Mouse Carbonic Anhydrase IX/CA9 Protein (His Tag)(Active) | PKSM040557 | Gentaur US, UK & Europe Disrtribition
Synonyms: RP23-195K8.9, CAIX, Ca9, MN/CA9
Active Protein: Active protein
Activity: A DNA sequence encoding the extracellular domain of mouse CAR9 (NP_647466.2) (Met 1-Asp 390) was expressed, with a C-terminal polyhistidine tag.
Protein Construction: A DNA sequence encoding the extracellular domain of mouse CAR9 (NP_647466.2) (Met 1-Asp 390) was expressed, with a C-terminal polyhistidine tag.
Fusion Tag: C-His
Species: Mouse
Expressed Host: HEK293 Cells
Shipping: This product is provided as lyophilized powder which is shipped with ice packs.
Purity: > 95 % as determined by reducing SDS-PAGE.
Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method.
Stability and Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.
Molecular Mass: 40.3 kDa
Formulation: Lyophilized from sterile PBS, pH 7.4
Reconstitution: Please refer to the printed manual for detailed information.
Background: Carbonic anhydrases IX (CA IX), also known as membrane antigen MN or CA9, is a member of the carbonic anhydrase (CA) family and may be involved in cell proliferation and cellular transformation. CAs are zinc metalloenzymes that catalyze the reversible hydration of carbon dioxide (H2O + CO2 = H+ + HCO3–) and thus participate in a variety of biological and physical processes. CA IX protein is expressed primarily in carcinoma cells lines, and the expression is cell density dependent and has been shown to be strongly induced by hypoxia, accordingly facilitates adaptation of tumor cells to hypoxic conditions. It is involved in tumorigenesis through many pathways, such as pH regulation and cell adhesion control. CA IX is used as a marker of tumor hypoxia and as a new therapeutic target for many human carcinomas and cancers.Immune Checkpoint Immunotherapy Cancer Immunotherapy Targeted Therapy
Research Area: N/A
